Log in to search using one of your social media accounts:

 

Perioperative Aspirin Might Benefit Patients with Prior PCI
Perioperative aspirin seems beneficial for high-risk patients undergoing noncardiac surgery who've previously undergone percutaneous coronary intervention (PCI), according to a subanalysis from the POISE... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2017 Category: Primary Care Source Type: news

Aspirin can prevent heart attacks after noncardiac surgery in patients with prior PCI
(University of Alberta Faculty of Medicine& Dentistry) A Canadian-led study has found that perioperative aspirin can prevent heart-related complications after major noncardiac surgery in patients with previous percutaneous coronary intervention (PCI) such as an angioplasty or stent. The study found that for every 1,000 patients with PCI, giving them aspirin at the time of noncardiac surgery would prevent 59 heart attacks and cause eight major bleeding events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Study: PCI Appears No Better Than Sham Procedure in Patients with Stable Angina (FREE)
By Kelly Young Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Percutaneous coronary intervention (PCI) didn't improve exercise time relative to a sham procedure in patients with stable angina and severe coronary stenosis. Findings from the ORBITA study were published in the Lancet and presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2017 Category: Primary Care Source Type: news

Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease
After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone (Source: Abbott.com)
Source: Abbott.com - November 2, 2017 Category: Pharmaceuticals Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

SCAI launches educational initiative as nation shifts to value-based healthcare
(Society for Cardiovascular Angiography and Interventions) The Society for Cardiovascular Angiography and Interventions announced today the launch of TRAnsition for VALUE, a multi-faceted educational initiative supported by Medtronic, to inform cardiologists, hospital administrators, and cath lab staff about the benefits of expanding the adoption of transradial (wrist access) percutaneous coronary intervention (PCI) in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
(American College of Cardiology) Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

Andreas Roland Gruentzig, the Man Andreas Roland Gruentzig, the Man
A fascinating profile of Andreas Gruentzig, the renowned cardiologist who first developed balloon angioplasty, and is considered the father of modern-day percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 20, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The 10 largest medical device companies in the world Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list. We pulled financial reg...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Reva Medical ’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Get the full story at our sister site, Drug Delivery...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Abbott Reva Medical Inc. Source Type: news

Study examines use of systolic blood pressure at time of primary percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for patients with STEMI range from 2.5% to 10%, and 10.5%-24% of those patients require mechanical hemodynamic support. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

BLS Crews in Paris Detect Atypical STEMI via 12-Lead ECG
By Jonathan Gonzva, MD; Laure Alhanati, MD; Stéphane Dubourdieu, MD; Daniel Jost, MD; Hugues Lefort, MD; Benoît Frattini, MD & Jean-Pierre Tourtier, MD A 61-year-old man calls the Paris Fire Brigade dispatch center with a complaint of dental pain. He reports feeling pain in the jaw for the past 35 minutes, which he says now extends to the armpits. He also reports that he experienced the same feeling the day before. The patient's age and hyperlipidemia were his only cardiovascular risk factors with atorvastatine and budesonide as the usual treatments. The physician stationed at the dispatch cen...
Source: JEMS Patient Care - September 7, 2017 Category: Emergency Medicine Tags: International Cardiac & Resuscitation Columns Patient Care Source Type: news

Rethinking dual antiplatelet guidelines in acute coronary syndrome? (CHANGE-DAPT)
(European Society of Cardiology) New research presented at ESC Congress today1 suggests that for acute coronary syndrome (ACS) patients who require percutaneous coronary intervention (PCI), treatment according to contemporary guidelines for dual anti-platelet therapy (DAPT) could be less preferable than sticking to older guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2017 Category: International Medicine & Public Health Source Type: news

Angioplasty outcomes almost equal among hospitals
Patients who undergo percutaneous coronary intervention have similar outcomes at different hospitals, researchers said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 8, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
MONDAY, Aug. 7, 2017 -- Patients who have an artery-opening procedure called percutaneous coronary intervention (PCI) have similar outcomes whether they're treated at so-called safety-net or non-safety-net hospitals, researchers say. Safety-net... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2017 Category: General Medicine Source Type: news

Blacks and Whites Have Similar Outcomes After PCI Blacks and Whites Have Similar Outcomes After PCI
A study designed to look for differing outcomes when black and white U.S. veterans undergo percutaneous coronary intervention (PCI) instead found no differences once confounding factors were taken into account.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 25, 2017 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news

Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
REDWOOD CITY, Calif., July 25, 2017 -- (Healthcare Sales & Marketing Network) -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distributi... Devices, Interventional, Cardiology, Distribution Roxwood Medical, Abbott, CenterCross, Percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news

Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)
Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year (...
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news

Heart vessel-clearing procedure can benefit some at age 90 and older
People in their nineties and older represent a tiny but growing fraction of patients who undergo a procedure called percutaneous coronary intervention (PCI) to clear blocked blood vessels in the heart, new research shows. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Prolonged DAPT After PCI: Risk Score Helps Identify Those Most Likely to Be Harmed (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The DAPT (dual antiplatelet therapy) score helps identify patients for whom prolonged treatment after percutaneous coronary intervention would be harmful, suggests an analysis in the Annals of Internal Medicine. Researchers retrospectively applied … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 13, 2017 Category: Primary Care Source Type: news

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Large multicenter study shows high success rate for robotic PCI procedures
Results from the PRECISION trial (Efficacy and Safety Outcomes of Radial- vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry) were presented today as a late-breaking clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2017 Category: Science Source Type: news

Blood Vessel-Clearing Procedure Riskier on Weekends: Study
THURSDAY, May 11, 2017 -- Although you often don't have a choice of when you get the heart procedure called percutaneous coronary intervention (PCI), new research suggests that having it done over the weekend may be more risky. The study reported... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 11, 2017 Category: General Medicine Source Type: news

Abiomed dips on missed Q4 earnings, despite sales beat
Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%. The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016. But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million. Full-year profits were $52.1 million, or $1.17 per share...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news

Cardiovascular Systems launches combined Diamondback 360, DES trial
Cardiovascular Systems (NSDQ:CSII) said today it enrolled the 1st patient in the Eclipse clinical trial of its Diamondback 360 coronary orbital atherectomy system. The St. Paul, Minn.-based company is looking to enroll 2,000 patients in the trial which aims to explore the use of the Diamondback 360 device for treating patients with severely calcified coronary lesions prior to drug-eluting stent placement. A control group will consist of patients treated with conventional angioplasty, including specialty balloons, prior to DES placement, the comapny said. The trial’s primary endpoint will be post-procedural minim...
Source: Mass Device - March 29, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Cardiovascular Systems Inc. Source Type: news

Teleflex (TFX) Announces 510(k) Clearance and U.S. Launch of Spectre(TM) Guidewire
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch ... Devices, Interventional, Cardiology, FDA, Product Launch Teleflex, Spectre Guidewire, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2017 Category: Pharmaceuticals Source Type: news

New Study Finds Abiomed Impella(R) Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
DANVERS, Mass., March 09, 2017 -- (Healthcare Sales & Marketing Network) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) can redu... Devices, Interventional, Cardiology Abiomed, Impella, Heart Pump, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2017 Category: Pharmaceuticals Source Type: news

Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk
Shorter percutaneous coronary intervention (PCI) procedures are associated with an increased risk of acute stent thrombosis (AST) in patients treated with bivalirudin, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news

Daiichi Sankyo begins enrolment in Phase IIIb trial of edoxaban to treat atrial fibrillation
Japanese-based pharmaceutical firm Daiichi Sankyo has begun enrolment in the Phase IIIb ENTRUST-AF PCI clinical trial of edoxaban for the treatment of atrial fibrillation patients who have undergone percutaneous coronary intervention (PCI) with stent … (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2017 Category: Pharmaceuticals Source Type: news

Radial access, same-day cardiac procedure could save $300 million annually
(American College of Cardiology) If hospitals can perform more transradial, same-day percutaneous coronary intervention, or PCIs, not only will patients benefit because it is associated with have less complications, but collectively, hospitals across the U.S. could save $300 million each year, according to research published today in JACC: Cardiovascular Interventions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Medtronic launches Signia stapler
Medtronic (NYSE:MDT) said today it launched its Signia stapling system in the US, Western Europe and Japan. The newly launched stapler from the Fridley, Minn.-based company includes Adaptive Firing technology which adjusts the stapler’s speed based on tissue variability measurements for more consistent staple lines. The device also includes 1-hand staple firing to allow for more operator freedom during procedures. “In my experience to date, I believe the articulation, rotation and firing of the Signia system provides an important new option in the performance of minimally invasive surgical procedures. Its abili...
Source: Mass Device - February 16, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Surgical Medtronic Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic launches DxTerity, TRA-line of radial access devices for PCIs
Medtronic (NYSE:MDT) today announced a slew of new percutaneous coronary intervention devices it added to its portfolio, including the DxTerity diagnostic angiography catheter line, the DxTerity TRA, InTRAkit transradial devices and the TRAcelet compression device. The Fridley, Minn.-based company said all of the items have already received FDA clearance in the US and CE Mark approval in the European Union for use in diagnostic cardiac catheterization procedures and percutaneous coronary interventions. Medtronic’s DxTerity and DxTerity TRA diagnostic catheters are designed to help determine whether revasculariza...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Medtronic Source Type: news

Abiomed gains after Abbott tables HeartMate PHP program
Abiomed (NSDQ:ABMD) shares closed up more than 5% yesterday as investors reacted to reports that Abbott (NYSE:ABT) paused its HeartMate PHP program in Europe. Abbott, which acquired the Thoratec line of HeartMate cardiac assist devices when it paid $25 billion for St. Jude Medical (NYSE:STJ) last month, reportedly advised physicians last week that it’s temporarily halting its Shield II clinical trial for the HeartMate PHP pump due to an issue with its catheter. Abbott said it “temporarily paused the HeartMate PHP Shield II IDE clinical trial as well as shipment and implantation of ...
Source: Mass Device - February 7, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Wall Street Beat Abbott Abiomed Inc. Source Type: news

Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors
In comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention (PCI) and hypothermia, ticagrelor results in faster and stronger platelet inhibition compared to clopidogrel, researchers in Slovenia say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 30, 2016 Category: Consumer Health News Tags: News Source Type: news

PCI Thrombus Aspiration Might Help Some PCI Thrombus Aspiration Might Help Some
Pooled data indicate that thrombus aspiration reduces cardiovascular mortality in certain patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Elective Surgery Delay After PCI May Be Safely Shortened Elective Surgery Delay After PCI May Be Safely Shortened
More than a month after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES), patients undergoing elective surgery appear to be at no greater risk than those without ischemic heart disease, according to Danish researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 21, 2016 Category: Surgery Tags: General Surgery News Source Type: news

Bayer ’s Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention (for specialized target groups only)
PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine (Source: Bayer Company News)
Source: Bayer Company News - November 14, 2016 Category: Pharmaceuticals Source Type: news

Phase 3b Study Shows Significantly Less Bleeding with XARELTO ® (rivaroxaban) Compared to Warfarin in People with Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention with Stenting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 14, 2016 Category: Pharmaceuticals Source Type: news

Enrollment completed for RE-DUAL PCI ™ study of 2,700 atrial fibrillation patients
(WHITECOAT STRATEGIES, LLC) The Baim Institute announces that patient enrollment into the international Phase IIIb RE-DUAL PCI ™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa ® ) in atrial fibrillation patients undergoing a percutaneous coronary intervention with stent placement. This is the first time that two dosages of a non-vitamin K antagonist oral anticoagulant already approved for stroke prevention in AF are evaluated in a dual versus triple antithrombotic regimen after PCI. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2016 Category: Global & Universal Source Type: news

Two differing medications used during heart procedure are both safe and effective, study finds
(Intermountain Medical Center) Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2016 Category: Global & Universal Source Type: news

Results of ReACT Trial presented at TCT & published in JACC: Cardiovascular Interventions
(Cardiovascular Research Foundation) A randomized evaluation of routine follow-up coronary angiography after percutaneous coronary intervention (PCI) found that there was no long-term clinical benefit compared to clinical follow-up alone among unselected patients following PCI. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 1, 2016 Category: Global & Universal Source Type: news

Guiding coronary stent implantation
Although percutaneous coronary intervention (PCI) is most commonly guided by angiography alone, results from a new study investigating adjunctive imaging modalities showed that the use of a novel optical coherence tomography (OCT)-based stent sizing strategy results in similar minimal stent area (MSA) compared to intravascular ultrasound (IVUS)-guided PCI. Imaging-guided PCI (with both OCT and IVUS) also resulted in improved stent expansion and acute stent-based procedural success compared to angiography-guided PCI. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 31, 2016 Category: Science Source Type: news

Results from the NOBLE trial presented at TCT 2016 and published in The Lancet
(Cardiovascular Research Foundation) Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic-Baltic-British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2016 Category: Global & Universal Source Type: news

One in three heart attack cases 'misdiagnosed'
Conclusion This valuable audit looks at nine years' worth of data from NHS hospitals, finding about a third of people with two forms of heart attack – STEMI and NSTEMI – are often wrongly diagnosed initially. These people are less likely to receive the guideline-indicated treatments they need – and the delay in receiving correct treatment could have a harmful effect. The study also highlights the factors associated with a wrong diagnosis, including being of an older age, having heart failure, and atypical findings for either diagnosis. Unexpectedly, gender was also associated with a wrong initial diagnos...
Source: NHS News Feed - August 30, 2016 Category: Consumer Health News Tags: Heart/lungs Medical practice Source Type: news

Longer duration of dual antiplatelet therapy after stent placement improves outcomes for patients with peripheral arterial disease
(The JAMA Network Journals) In a study published online by JAMA Cardiology, Marco Valgimigli, M.D., Ph.D., of Bern University Hospital, Bern, Switzerland, and colleagues assessed the efficacy and safety of prolonged (24 months) vs short (6 months or less) dual antiplatelet therapy in patients with peripheral arterial disease undergoing percutaneous coronary intervention. The study is being released to coincide with its presentation at the European Society of Cardiology Congress 2016. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2016 Category: Global & Universal Source Type: news

DOCTORS trial: Invasive imaging sheds more light on percutaneous coronary intervention
(European Society of Cardiology) An invasive imaging technique called optical coherence tomography can visualize the coronary arteries in patients undergoing percutaneous coronary intervention (PCI) and lead to better outcomes compared to standard angiography-guided PCI, according to new findings reported here. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - August 29, 2016 Category: Global & Universal Source Type: news

Naciam: N-acetylcysteine offers a post-MI boost
The addition of intravenous (IV) N-acetylcysteine (NAC) to IV glyceryl trinitrate (GTN) significantly reduced infarct size by approximately one third in patients undergoing percutaneous coronary intervention (PCI) after ST-segment elevation acute myocardial infarction (STEMI), according to Hot Line research reported here. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 28, 2016 Category: Science Source Type: news